282 related articles for article (PubMed ID: 15970668)
1. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Burger H; van Tol H; Brok M; Wiemer EA; de Bruijn EA; Guetens G; de Boeck G; Sparreboom A; Verweij J; Nooter K
Cancer Biol Ther; 2005 Jul; 4(7):747-52. PubMed ID: 15970668
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
Théou N; Gil S; Devocelle A; Julié C; Lavergne-Slove A; Beauchet A; Callard P; Farinotti R; Le Cesne A; Lemoine A; Faivre-Bonhomme L; Emile JF
Clin Cancer Res; 2005 Nov; 11(21):7593-8. PubMed ID: 16278376
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib.
Burger H; Nooter K
Cell Cycle; 2004 Dec; 3(12):1502-5. PubMed ID: 15611623
[TBL] [Abstract][Full Text] [Related]
4. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.
Albermann N; Schmitz-Winnenthal FH; Z'graggen K; Volk C; Hoffmann MM; Haefeli WE; Weiss J
Biochem Pharmacol; 2005 Sep; 70(6):949-58. PubMed ID: 16054595
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
6. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
[TBL] [Abstract][Full Text] [Related]
7. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
Eadie LN; Saunders VA; Hughes TP; White DL
Leuk Lymphoma; 2013 Mar; 54(3):569-78. PubMed ID: 22845311
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
9. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Gromicho M; Dinis J; Magalhães M; Fernandes AR; Tavares P; Laires A; Rueff J; Rodrigues AS
Leuk Lymphoma; 2011 Oct; 52(10):1980-90. PubMed ID: 21663515
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Burger H; van Tol H; Boersma AW; Brok M; Wiemer EA; Stoter G; Nooter K
Blood; 2004 Nov; 104(9):2940-2. PubMed ID: 15251980
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
13. Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
Gardner ER; Smith NF; Figg WD; Sparreboom A
J Exp Clin Cancer Res; 2009 Jul; 28(1):99. PubMed ID: 19591692
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
[TBL] [Abstract][Full Text] [Related]
15. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer.
Chen M; Xue X; Wang F; An Y; Tang D; Xu Y; Wang H; Yuan Z; Gao W; Wei J; Zhang J; Miao Y
Oncol Rep; 2012 Jan; 27(1):265-9. PubMed ID: 21956451
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.
Davies A; Jordanides NE; Giannoudis A; Lucas CM; Hatziieremia S; Harris RJ; Jørgensen HG; Holyoake TL; Pirmohamed M; Clark RE; Mountford JC
Leukemia; 2009 Nov; 23(11):1999-2006. PubMed ID: 19710702
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Campa D; Butterbach K; Slager SL; Skibola CF; de Sanjosé S; Benavente Y; Becker N; Foretova L; Maynadie M; Cocco P; Staines A; Kaaks R; Boffetta P; Brennan P; Conde L; Bracci PM; Caporaso NE; Strom SS; Camp NJ; Cerhan JR; ; Canzian F; Nieters A
Int J Cancer; 2012 Aug; 131(4):803-12. PubMed ID: 21918980
[TBL] [Abstract][Full Text] [Related]
18. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
19. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
20. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
